| Product/ Candidate |
Therapeutic Area |
Discovery and Translation |
POC | Pivotal | Commercial | Content Partner |
Development Partner |
|---|---|---|---|---|---|---|---|
 |
Substance Use Disorder |  |
|||||
 |
Opioid Use Disorder | |
|||||
 * |
Insomnia/Depression |  |
|||||
| PEAR-004* | Schizophrenia |  |
|||||
| DISCOVERY* | IBS |  ** |
|||||
| DISCOVERY* | Pain |  |
|||||
| DISCOVERY* | PTSD |  |
|||||
| DISCOVERY* | Migraine |  |
|||||
| DISCOVERY* | Bipolar Disorder | ||||||
| PEAR-006* | Multiple Sclerosis | |
|||||
| DISCOVERY* | Epilepsy | ||||||
| DISCOVERY* | Specialty GI |  *** |
|||||
| DISCOVERY* | Oncology |  |
|||||
| PLATFORM | Voice Analytics |   |
|||||
INTERNAL PARTNERED
* FDA has not determined the safety or effectiveness of this product candidate.
** Licensed content from individual researchers employed by the Karolinska Institute.
*** Pear entered into a services agreement with Ironwood to evaluate a PDT in GI diseases.